Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of ...(erally welltolerated and continues to de...),Health

In addition to the KRX-0401 abstract which was selected for oral presentation, four abstracts on KRX-0401 were accepted for poster presentation. All of the clinical data to be presented demonstrates the potential efficacy of KRX-0401, both as a single agent and in combination with other approved agents, in the treatment of patients with multiple myeloma and waldenstrom's macroglobulinemia.

"We are encouraged by the safety and efficacy results obtained to date on the combination of KRX-0401 and bortezomib in relapsed and refractory multiple myeloma patients who were all previously treated with bortezomib," said Michael S. Weiss, Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc., who continued "we plan to further evaluate the potential efficacy of KRX-0401 as a treatment for multiple myeloma and related disorders and continue to explore the design of a phase 3 program in multiple myeloma."

Summary of KRX-0401 Data Presentations

ORAL PRESENTATION: TUESDAY, DECEMBER 9th

Abstract 870

Title: Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401)

+ Bortezomib in Patients with Relapsed or Relapsed / Refractory Multiple

Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

Session Name: Novel Therapies for Myeloma and Related Disorders Session

(7:00- 9:00 AM)

Presentation Time: 8:30am

Location: Gateway Ballroom 103 - South

Clinical Poster Presentations:

SATURDAY, DECEMBER 6th

Abstract 1010

TITLE: Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor

Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

(WM)

Session Name: Biologic Therapies for NHL (Ex
'/>"/>